Overview
AXSM market data
Price History
AXSM price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for AXSM. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Axsome Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $310.Benzinga · Jul 21, 2026, 7:00 PM
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For TuesdayBenzinga · Jul 21, 2026, 3:14 PM
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 21, 2026, 11:58 AM
BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $310Benzinga · Jul 21, 2026, 9:48 AM
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price TargetBenzinga · Jul 15, 2026, 5:14 PM
8-K filing — Axsome Therapeutics, Inc. (AXSM)SEC EDGAR · Jul 15, 2026, 11:05 AM
Axsome Therapeutics Says FDA Accepts NDA For AXS-12 For Treatment Of Cataplexy In Narcolepsy; PDUFA Target Action Date Set May 1, 2027Benzinga · Jul 15, 2026, 11:03 AM
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10Globenewswire Inc · Jul 14, 2026, 11:15 AM
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $304Benzinga · Jul 7, 2026, 4:15 PM
Axsome Therapeutics Doses First Patient In FOCUS-2 Phase 3 Trial Of Solriamfetol For Children With Attention Deficit Hyperactivity DisorderBenzinga · Jul 7, 2026, 11:10 AM